Parkinson's Disease Research Today is a free monthly online journal that collates and summarizes the latest research about Parkinson's Disease, including details on symptoms, treatment, genetics, medication.

Volume 2 (2005), Issue 2 (February)

1. Coexpression of tyrosine hydroxylase, GTP cyclohydrolase I, aromatic amino acid decarboxylase, and vesicular monoamine transporter 2 from a helper virus-free herpes simplex virus type 1 vector supports high-level, long-term biochemical and behavioral correction of a rat model of Parkinson's disease.
   Hum Gene Ther, 15(12): 1177-96. [Abstract] [Full-text]
2. Pharmacological manipulation of ataxia-telangiectasia kinase activity as a treatment for Parkinson's disease.
   Med Hypotheses, 64(4): 736-41. [Abstract] [Full-text]
3. Analysis of the trinucleotide CAG repeat from the DNA polymerase gamma gene (POLG) in patients with Parkinson's disease.
   Neurosci Lett, 376(1): 56-9. [Abstract] [Full-text]
4. No associations between Parkinson's disease and polymorphisms of the quinone oxidoreductase (NQO1, NQO2) genes.
   Neurosci Lett, 375(3): 178-80. [Abstract] [Full-text]
5. Impaired gastric emptying of a solid test meal in patients with Parkinson's disease using 13C-sodium octanoate breath test.
   Neurosci Lett, 375(3): 170-3. [Abstract] [Full-text]
6. Remarkable effect of milnacipran, a serotonin-noradrenalin reuptake inhibitor (SNRI), on depressive symptoms in patients with Parkinson's disease who have insufficient response to selective serotonin reuptake inhibitors (SSRIs): two case reports.
   Prog Neuropsychopharmacol Biol Psychiatry, 29(2): 351-3. [Abstract] [Full-text]
7. Sleep and sleepiness in patients with Parkinson's disease before and after dopaminergic treatment.
   Eur J Neurol, 12(3): 199-207. [Abstract] [Full-text]
8. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease.
   Neurology, 64(3): 545-7. [Abstract] [Full-text]
9. Family-based case-control study of cigarette smoking and Parkinson disease.
   Neurology, 64(3): 442-7. [Abstract] [Full-text]
10. Study of familial Parkinson's disease in Russia, Uzbekistan, and Zambia.
    Postgrad Med J, 81(952): 117-21. [Abstract] [Full-text]
11. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated Parkinsonism.
    J Cogn Neurosci, 17(1): 51-72. [Abstract] [Full-text]
12. Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
    Proc Natl Acad Sci U S A, 102(6): 2162-7. [Abstract] [Full-text]
13. Parkin-deficient mice are not a robust model of parkinsonism.
    Proc Natl Acad Sci U S A, 102(6): 2174-9. [Abstract] [Full-text]
14. Atypical cancer pattern in patients with Parkinson's disease.
    Br J Cancer, 92(1): 201-5. [Abstract] [Full-text]
15. Rigidity and bradykinesia reduce interlimb coordination in Parkinsonian gait.
    Arch Phys Med Rehabil, 86(2): 183-9. [Abstract] [Full-text]
16. The amygdala of patients with Parkinson's disease is silent in response to fearful facial expressions.
    Neuroscience, 131(2): 523-34. [Abstract] [Full-text]
17. Parkinson's disease in China: prevalence in Beijing, Xian, and Shanghai.
    Lancet, 365(9459): 595-7. [Abstract] [Full-text]
18. Acanthopanax senticosus Harms as a prophylactic for MPTP-induced Parkinson's disease in rats.
    J Ethnopharmacol, 97(2): 375-81. [Abstract] [Full-text]
19. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease.
    Neurochem Int, 46(4): 329-35. [Abstract] [Full-text]
20. Effects of disease progression and L-dopa therapy on the control of reaching-grasping in Parkinson's disease.
    Neuropsychologia, 43(3): 450-9. [Abstract] [Full-text]
21. Structural brain changes in Parkinson disease with dementia: a voxel-based morphometry study.
    Arch Neurol, 62(2): 281-5. [Abstract] [Full-text]
22. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Arch Neurol, 62(2): 241-8. [Abstract] [Full-text]
23. Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease.
    Neurosci Res, 51(3): 299-308. [Abstract] [Full-text]
24. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
    Brain, 128: 570-83. [Abstract] [Full-text]
25. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-DOPA delivery using rAAV vectors.
    Brain, 128: 559-69. [Abstract] [Full-text]
26. Differentiation of Parkinson's disease and atypical parkinsonian syndromes by transcranial ultrasound.
    J Neurol Neurosurg Psychiatry, 76(3): 423-5. [Abstract] [Full-text]
27. Targeting the subthalamic nucleus for deep brain stimulation: technical approach and fusion of pre- and postoperative MR images to define accuracy of lead placement.
    J Neurol Neurosurg Psychiatry, 76(3): 409-14. [Abstract] [Full-text]
28. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach.
    J Neurol Neurosurg Psychiatry, 76(3): 343-8. [Abstract] [Full-text]
29. Event-related potentials for response inhibition in Parkinson's disease.
    Neuropsychologia, 43(6): 967-75. [Abstract] [Full-text]
30. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease.
    Neuropsychologia, 43(6): 823-32. [Abstract] [Full-text]
31. Lack of inhibition in Parkinson's disease: evidence from a lexical decision task.
    Neuropsychologia, 43(4): 638-46. [Abstract] [Full-text]
32. Glutathione depletion resulting in selective mitochondrial complex I inhibition in dopaminergic cells is via an NO-mediated pathway not involving peroxynitrite: implications for Parkinson's disease.
    J Neurochem, 92(5): 1091-103. [Abstract] [Full-text]
33. New hope for mechanism-based treatment of Parkinson's disease.
    Drug Discov Today, 10(2): 80-1. [Abstract] [Full-text]
34. Cortical 6-[18F]fluoro-L-dopa uptake and frontal cognitive functions in early Parkinson's disease.
    Neurobiol Aging, 26(6): 891-8. [Abstract] [Full-text]
35. Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson's disease.
    Neuropsychopharmacology, 30(3): 590-601. [Abstract] [Full-text]
36. Without DJ-1, the D2 receptor doesn't play.
    Neuron, 45(4): 479-81. [Abstract] [Full-text]
37. Degradation of postural control system as a consequence of Parkinson's disease and ageing.
    Neurosci Lett, 376(3): 215-20. [Abstract] [Full-text]
38. Deficits in saccadic eye-movement control in Parkinson's disease.
    Neuropsychologia, 43(5): 784-96. [Abstract] [Full-text]
39. Impaired intentional content learning but spared incidental retention of contextual information in non-demented patients with Parkinson's disease.
    Neuropsychologia, 43(5): 675-81. [Abstract] [Full-text]
40. Levodopa-induced dyskinesia in Parkinson's disease.
    J Neural Transm, 112(3): 359-91. [Abstract] [Full-text]
41. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years.
    Mov Disord, 20(2): 190-9. [Abstract] [Full-text]
42. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model.
    Mov Disord, 20(2): 130-40. [Abstract] [Full-text]
43. Cigarette smoking and Parkinson's disease: a case-control study in a population characterized by a high prevalence of pesticide exposure.
    Mov Disord, 20(2): 181-9. [Abstract] [Full-text]
44. No global loss of neocortical neurons in Parkinson's disease: a quantitative stereological study.
    Mov Disord, 20(2): 164-71. [Abstract] [Full-text]
45. Hallucinations in Parkinson's disease: a follow-up study.
    Mov Disord, 20(2): 212-7. [Abstract] [Full-text]
46. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges.
    Mov Disord, 20(2): 151-7. [Abstract] [Full-text]
47. Visual kinesthesia and locomotion in Parkinson's disease.
    Mov Disord, 20(2): 141-50. [Abstract] [Full-text]
48. Salivary production in Parkinson's disease.
    Mov Disord, 20(2): 204-7. [Abstract] [Full-text]
49. Impact of the motor complications of Parkinson's disease on the quality of life.
    Mov Disord, 20(2): 224-30. [Abstract] [Full-text]
50. Memory-guided saccades in Parkinson's disease: long delays can improve performance.
    Exp Brain Res, 161(3): 293-8. [Abstract] [Full-text]
51. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany.
    J Neurol, 252(2): 218-23. [Abstract] [Full-text]
52. High frequency stimulation of the subthalamic nucleus is efficacious in Parkin disease.
    J Neurol, 252(2): 208-11. [Abstract] [Full-text]
53. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD--a comparison of neuropsychological effects.
    J Neurol, 252(2): 176-82. [Abstract] [Full-text]
54. REM sleep behaviour disorder in Parkinson's disease: a questionnaire-based study.
    Neurol Sci, 25(6): 316-21. [Abstract] [Full-text]
55. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation.
    J Neurosci, 25(8): 2002-9. [Abstract] [Full-text]
56. Parkinson's disease: the first common neurological disease due to auto-intoxication?
    QJM, 98(3): 215-26. [Abstract] [Full-text]
57. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study.
    Neurology, 64(4): 728-30. [Abstract] [Full-text]
58. "Off" gait freezing and temporal discrimination threshold in patients with Parkinson disease.
    Neurology, 64(4): 670-4. [Abstract] [Full-text]
59. Physical activity and the risk of Parkinson disease.
    Neurology, 64(4): 664-9. [Abstract] [Full-text]
60. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
    Parkinsonism Relat Disord, 11(2): 131-3. [Abstract] [Full-text]
61. Memory perception and strategy use in Parkinson's disease.
    Parkinsonism Relat Disord, 11(2): 111-5. [Abstract] [Full-text]
62. The effect of directing attention during walking under dual-task conditions in Parkinson's disease.
    Parkinsonism Relat Disord, 11(2): 95-9. [Abstract] [Full-text]
63. Bilateral subthalamic nucleus stimulation improves health-related quality of life in Parkinsonian patients.
    Parkinsonism Relat Disord, 11(2): 89-94. [Abstract] [Full-text]
64. Is there a relationship between Parkinson's disease and obsessive-compulsive disorder?
    Parkinsonism Relat Disord, 11(2): 85-8. [Abstract] [Full-text]
65. Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease.
    Parkinsonism Relat Disord, 11(2): 81-4. [Abstract] [Full-text]
66. Correspondence of microelectrode mapping with magnetic resonance imaging for subthalamic nucleus procedures.
    Surg Neurol, 63(3): 249-53; discussion 253. [Abstract] [Full-text]
67. Visual and spatial symptoms in Parkinson's disease.
    Vision Res, 45(10): 1285-96. [Abstract] [Full-text]

© 2004-2008 Parkinson's Disease Research Today. All Rights Reserved.